Results 201 to 210 of about 97,767 (354)

Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer. [PDF]

JCO Precis Oncol
Kapil A, Failmezger H, Fu Y, Spitzmüller A, Chan J, Haneder S, Shumilov A, Barkell A, Oguma T, Inaki K, Suto F, Allard J, Lee J, Lambert AW, Schick M, Barrett JC, Schmidt G, Sade H, Gustavson M, Carroll D, Cecchi F.   +20 more
europepmc   +1 more source

The family : its fungtion and destiny

, 1949
xi, 443 p.; 24 ...
Anshen, Ruth Nanda
core  

HNRNPD Induces Radioresistance in Nasopharyngeal Carcinoma by Sequestering GRAMD4 mRNA in Stress Granules

Advanced Science, EarlyView.
HNRNPD promotes radioresistance in nasopharyngeal carcinoma by enhancing stress granule assembly and sequestering GRAMD4 mRNA. This suppresses GRAMD4 translation and inhibits mitochondrial apoptosis. Targeting the integrated stress response with ISRIB restores GRAMD4 expression and sensitizes tumors to radiotherapy, revealing a translational control ...
Yingzi Li, Tong Xiang, Yuanyuan Liu, Desheng Weng, Jingjing Zhao, Hao Chen, Yan Tang, Songzuo Xie, Hao Zhang, Jun Luo, Xinyi Yang, Qiuzhong Pan, Muping Di, Jianchuan Xia   +13 more
wiley   +1 more source

Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: a systematic review and indirect treatment comparison. [PDF]

Front Oncol
Cappuzzo F, Zhang L, Dunton K, Dennis N, Le Nouveau P, Nevière A, Gauthier A.   +6 more
europepmc   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source

Islamic perspectives of spiritual needs in patients with breast cancer: A qualitative study. [PDF]

J Taibah Univ Med Sci
Rahayu DA, Sukartini T, Bakar A, Nurhalimah N.   +3 more
europepmc   +1 more source

UCHL3 Regulates Subgenomic Flaviviral RNA Condensates to Promote Virus Propagation

Advanced Science, EarlyView.
ABSTRACT Flavivirus subgenomic RNAs (sfRNAs) antagonise antiviral defences, yet how sfRNAs are organized and maintained in cells remains poorly understood. Here we identify ubiquitin C‐terminal hydrolase L3 (UCHL3) as a post‐translational regulator of flavivirus sfRNA stability and function.
Oscar Trejo‐Cerro, Anna Beekmayer‐Dhillon, Qi Wen Teo, Lewis Siu, Ming Yuan Li, Kate J. Heesom, Adán Pinto‐Fernández, Sumana Sanyal   +7 more
wiley   +1 more source

Surgical Resection of Metastatic Male Breast Cancer to the Brain: An Illustrative Case Report. [PDF]

Clin Case Rep
Pio F, Fleisher MS, Obeidallah M, Mitchell M, Daggubati L.   +4 more
europepmc   +1 more source

Stress History Establishes a Transient Tolerant State That Shapes Antibiotic Survival Upon Resuscitation

Advanced Science, EarlyView.
High‐throughput single‐cell analysis of resuscitating bacteria reveals a starvation‐history‐dependent transiently tolerant subpopulation that survives β$\beta$‐lactam exposure by temporarily reducing growth. Distinct from classical persisters, these actively growing yet dynamically modulated cells dominate survival across clinically relevant antibiotic
Kieran Abbott, Georgeos Hardo, Ruizhe Li, Jack Bradley, Ashraf Zarkan, Somenath Bakshi   +5 more
wiley   +1 more source

DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer. [PDF]

ESMO Gastrointest Oncol
Janjigian YY, Smyth E, Shen L, Lee J, Hoff PM, Lonardi S, Barrios D, Kobayashi K, Okuda Y, Kamio T, Shitara K.   +10 more
europepmc   +1 more source